Articles tagged with Cytokine Therapy
Researchers developed a method to inhibit lipid nanoparticle migration into the liver by coating hepatic sinusoidal walls with polyethylene glycol. This coating reduced liver accumulation by several dozen times and increased protein expression in the spleen, promoting safer nanomedicine with lower dosages.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers at Tulane University discovered that breast cancer cells use complex immune-modulatory programs to evade immune clearance, leading to treatment resistance. They identified 16 immune checkpoint genes and found that chemotherapy triggers a program of immune checkpoints that shield cancer cells from different lines of attack.
Researchers at UC Davis Health developed a new treatment that simultaneously blocks IL-6 and TNF cytokines, providing superior protection against acute graft-versus-host-disease severity and mortality. The dual-cytokine blockade approach did not impair beneficial graft-versus-tumor effects.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers discovered that cytokine therapy enhances natural killer cell functions against tumors lacking MHC class I. The treatment restored NK cell activity and reduced tumor size in mice, supporting further investigation into its potential as a cancer treatment.